rss
Evid Based Med 7:13 doi:10.1136/ebm.7.1.13
  • Therapeutics

Review: angiotensin-converting enzyme inhibitors reduce the progression of non-diabetic renal disease

Antihypertensive regimens with angiotensin-converting enzyme (ACE) inhibitors (treatment) v regimens without ACE inhibitors (control)*

Weighted event rates
Outcomes at 2 to 4 years Treatment Control RRR (95% CI) NNT (CI)
ESRD 10.5% 11.5% 34% (14 to 50) 102 (36 to 114)
Doubling of serum creatinine or ESRD 15.7% 20.3% 34% (18 to 47) 22 (11 to 257)
ESRD or death 11.1% 12.7% 23% (–7 to 45) Not significant
RRI (CI) NNH
*ESRD = end stage renal disease. Other abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated from data provided by author using a random effects model.
†A fixed effects model was used.
Death† 2.4% 1.2% 63% (−219 to 16) Not significant

This Article

Latest from the blog

Latest from the blog


Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.